VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...

While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

National Geographic photographer Josh Cogan captures the quiet power of Hawaii’s ocean life, revealing how resilience shows ...

(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...

The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...

Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

HK Innoen is accelerating the expansion of its portfolio in geriatric and metabolic diseases by launching full-scale development of a treatment for ...

CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

The previous quarter showed revenue of $396k and a loss of $36.77 million. This valuation on DNTH is abysmal. Price-to-Sales ...